Italia markets open in 8 hours 30 minutes
  • Dow Jones

    29.683,74
    +548,75 (+1,88%)
     
  • Nasdaq

    11.051,64
    +222,13 (+2,05%)
     
  • Nikkei 225

    26.173,98
    -397,89 (-1,50%)
     
  • EUR/USD

    0,9728
    +0,0130 (+1,35%)
     
  • BTC-EUR

    20.150,25
    +406,96 (+2,06%)
     
  • CMC Crypto 200

    447,10
    +18,32 (+4,27%)
     
  • HANG SENG

    17.250,88
    -609,43 (-3,41%)
     
  • S&P 500

    3.719,04
    +71,75 (+1,97%)
     

OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022

·1 minuto per la lettura
Opko Health, Inc.
Opko Health, Inc.

MIAMI, July 25, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2022 after the close of the U.S. financial markets on Thursday, August 4, 2022. OPKO’s senior management will provide a business update and discuss financial results as well as financial guidance during a conference call and live audio webcast on August 4th beginning at 4:30 p.m. Eastern time.

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will be given a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing (833) 630-0584 (U.S.) or (412) 317-1815 (International). A webcast of the call may also be accessed at OPKO’s Investor Relations page and here.

A telephone replay will be available until August 11, 2022 by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 5775821. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

Contacts:

LHA Investor Relations
Yvonne Briggs, 310-691-7100
ybriggs@lhai.com 
or
Bruce Voss, 310-691-7100
bvoss@lhai.com